Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥ 18 yrs and \<70 yrs with histologically or cytologically confirmed~* Malignant disease~* Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60~* Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60 \~ 80 mg/m2 on study Day 1~* Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit~* Patients with hepatic, renal, or cardiovascular impairment eligible at the investigator's discretion~* Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at the investigator's discretion~* Predicted life expectancy of ≥ 3 months~* Provision of written informed consent.~Exclusion Criteria:~* Inability to understand or cooperate with study procedures~* Receipt of investigational drugs ≤ 30 days before study entry~* Receipt of other investigational drugs during the course of this study~* Seizure disorder or any condition requiring anticonvulsants, sedatives~* CNS malignancy or metastasis~* Ongoing emesis due to obstruction of digestive tract~* Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy~* Moderate or severe nausea and vomiting after any previous chemotherapy~* Scheduled receipt of any chemotherapeutic agent with an emetogenicity level \>3 during study Days 2-5~* Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5~* Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of study initiation and throughout day 5~* Contraindications to 5-HT3 receptor antagonists~* Contraindications to chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).